The choice between ICD types still should be based on each individual patient’s risk factors, Kenneth Ellenbogen says.

The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.

The US guidelines are likely to change following the release of the VANISH2 results last year, Christine Albert anticipates.